Spots Global Cancer Trial Database for hormone refractory
Every month we try and update this database with for hormone refractory cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer | NCT00116142 | Prostate Cancer | Docetaxel Androgen Hormon... Androgen Suppre... | 30 Years - | Dana-Farber Cancer Institute | |
| Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer | NCT00673127 | Prostate Cancer | Ketoconazole, H... | 18 Years - | Dana-Farber Cancer Institute | |
| ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | NCT00415779 | Metastatic Pros... | docetaxel zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone | NCT00291005 | Prostatic Neopl... | ARD6562, Doceta... | 20 Years - 74 Years | Sanofi | |
| Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy | NCT00895310 | Prostate Cancer | Ketoconazole Hydrocortisone | 18 Years - | University of California, Davis | |
| PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone | NCT00291005 | Prostatic Neopl... | ARD6562, Doceta... | 20 Years - 74 Years | Sanofi | |
| Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | NCT00411528 | Metastatic Horm... | Patupilone prednisone docetaxel | 18 Years - | Novartis | |
| Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | NCT00176293 | Prostate Cancer | dexamethasone doxorubicin | 18 Years - | University of Kentucky | |
| Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | NCT00411528 | Metastatic Horm... | Patupilone prednisone docetaxel | 18 Years - | Novartis | |
| E3-Hormone Refractory Prostrate Cancer Taxotere Combination | NCT00498797 | Prostate Cancer Metastatic Hormone Refract... | Zactima (vandet... Docetaxel Prednisolone | 18 Years - | Sanofi | |
| Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer | NCT00132756 | Prostate Cancer | Doxil and Estra... | 18 Years - | Morton Plant Mease Health Care | |
| Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis | NCT02097303 | Prostate Cancer | Concurrent use ... | 18 Years - | Carolina Research Professionals, LLC | |
| Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00103428 | Prostate Cancer | CG7870 | 18 Years - | Cell Genesys | |
| Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer | NCT00582582 | Prostate Cancer | Docetaxel plus ... Docetaxel plus ... | 18 Years - | University of Wisconsin, Madison | |
| Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | NCT00065442 | Prostate Cancer | Sipuleucel-T APC-Placebo | 18 Years - | Dendreon | |
| ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | NCT00415779 | Metastatic Pros... | docetaxel zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC | NCT00286793 | Prostate Cancer | AT-101 | 18 Years - | Ascenta Therapeutics | |
| ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | NCT00061126 | Prostate Cancer | ABX-EGF | 18 Years - | Abgenix | |
| Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | NCT00545766 | Prostate Cancer | Vinflunine | 18 Years - | SCRI Development Innovations, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
